**10. Future developments**

There are a number of areas currently at a research stage that may be of benefit in the man‐ agement of CFRD.

Many centres are moving away from a reliance on the standard 2-hour OGTT to diagnose CFRD, with the use of CGM becoming more widespread to detect clinically significant dysglycemia at an earlier stage.

A number of clinical trials are exploring the use of incretin based therapy in individuals with CF [82, 83] and such therapies theoretically offer an ideal combination of glucose lowering effects with a smaller risk of precipitating hypoglycaemia, especially as con‐ cerns about the risk of pancreatitis associated with these type of medications have somewhat lessened recently [84].

Ultimately novel experimental treatments being developed for other forms of diabetes such as stem cell implantation may be applicable to individuals with CFRD.
